Assessment of efficiency and safety of adenovirus mediated gene transfer into normal and damaged murine livers

Gut

Volumn 47, Issue 4, 2000, Pages 563-570

  Nakatani, T ^a   Fukui, H ^a   Kuriyama, S ^a   Tominaga, K ^a   Tsujimoto, T ^a   Mitoro, A ^a   Yamazaki, M ^a   Tsujinoue, H ^a   Yoshiji, H ^a   Nagao, S ^a  

^a NARA MEDICAL UNIVERSITY   (Japan)

Author keywords

Adenovirus; Fulminant hepatitis; Liver cirrhosis; Safety; Transduction efficiency

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; BETA GALACTOSIDASE; BILIRUBIN; CHOLINESTERASE; CREATININE; ESCHERICHIA COLI LIPOPOLYSACCHARIDE; GALACTOSAMINE; LACTATE DEHYDROGENASE; NEUTRALIZING ANTIBODY; THIOACETAMIDE;

ADENOVIRUS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CHEMOLUMINESCENCE; CONTROLLED STUDY; ENZYME ACTIVITY; FEMALE; GENE EXPRESSION; GENE TRANSFER; GENETIC TRANSDUCTION; HEPATITIS; HISTOCHEMISTRY; LIVER CIRRHOSIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; SAFETY; T LYMPHOCYTE ACTIVATION; TRANSGENE; VIRUS RECOMBINANT;

ADENOVIRIDAE; ANIMALS; BETA-GALACTOSIDASE; CHEMILUMINESCENT MEASUREMENTS; ESCHERICHIA COLI; FEMALE; GENE TRANSFER TECHNIQUES; GENETIC VECTORS; HEPATITIS, ANIMAL; LIVER CIRRHOSIS, EXPERIMENTAL; MICE; MICE, INBRED BALB C; STAINING AND LABELING; TREATMENT OUTCOME;

EID: 0033804496     PISSN: 00175749     EISSN: None     Source Type: Journal    
DOI: 10.1136/gut.47.4.563     Document Type: Article

References (48)

1. 1 Strauss SE. The adenoviruses. Ginsberg HS, ed. The adenoviruses. New York: Plenum Press, 1984:451-96.
2. 2 Rosenfeld MA, Yoshimura K, Trapnell BC, et al. In vivo transfer of the human cystic fibrosis transmembrane conductance regulator gene to the airway epithelium. Cell 1992;68:143-55.
3. 3 Zabner J, Couture LA, Gregory RJ, et al. Adenovirus-mediated gene transfer transiently corrects the chloride transport defect in nasal epithelia of patients with cystic fibrosis. Cell 1993;75:207-16.
4. 4 Crystal RG, McElvaney NG, Rosenfeld MA, et al. Administration of an adenovirus containing the human CFTR cDNA to the respiratory tract of individuals with cystic fibrosis. Nat Genet 1994;8:42-51.
5. 5 Stratford-Perricaudet LD, Levrero M, Chasse JF, et al. Evaluation of the transfer and expression in mice of an enzyme-encoding gene using a human adenovirus vector. Hum Gene Ther 1990;1:241-56.
6. 6 Jaffe H, Danel C, Longenecker G, et al. Adenovirus-mediated in vivo gene transfer and expression in normal rat liver. Nat Genet 1992;1:372-8.
7. 7 Kay MA, Landen CN, Rothenberg SR, et al. In vivo hepatic gene therapy: complete albeit transient correction of factor IX deficiency in hemophilia B dogs. Proc Natl Acad Sci USA 1994;91:2353-7.
8. 8 Ishibashi S, Brown MS, Goldstein JL, et al. Hypercholesterolemia in low density lipoprotein receptor knockout mice and its reversal by adenovirus-mediated gene delivery. J Clin Invest 1993;92:883-93.
9. 9 Kozarsky KF, McKinley DR, Austin LL, et al. In vivo correction of low density lipoprotein receptor deficiency in the Watanabe Heritable hyperlipidemic rabbit with recombinant adenoviruses. J Biol Chem 1994;269:13695-702.
10. 10 Pinkert CA, Ornitz DM, Brinster RL, et al. An albumin enhancer located 10 kb upstream functions along with its promoter to direct efficient, liver-specific expression in transgenic mice. Gene Dev 1987;1:268-76.
11. 11 Kuriyama S, Yoshikawa M, Ishizaka S, et al. A potential approach for gene therapy targeting hepatoma using a liver-specific promoter on a retroviral vector. Cell Struct Funct 1991;16:503-10.
12. 12 Crystal RG. Transfer of genes to humans: early lessons and obstacles to success. Science 1995;270:404-10.
13. 13 Sullivan DE, Dash S, Du H, et al. Liver-directed gene transfer in non-human primates. Hum Gene Ther 1997;8:1195-206.
14. 14 Nakamura Y, Wakimoto H, Abe J, et al. Adoptive immunotherapy with murine tumor-specific T lymphocytes engineered to secrete interleukin 2. Cancer Res 1994;54:5757-60.
15. 15 Niwa H, Yamamura K, Miyazaki J, et al. Efficient selection for high-expression transfectants with a novel eukaryotic vector. Gene 1991;108:193-200.
16. 16 Miyake S, Makimura M, Kanegae Y, et al. Efficient generation of recombinant adenoviruses using adenovirus DNA-terminal protein complex and a cosmid bearing the full-length virus genome. Proc Natl Acad Sci USA 1996;93: 1320-4.
17. 17 Graham FL, Prevec L. Manipulation of adenovirus vectors. In: Murray EJ, ed. Methods in molecular biology. Clifton: Humana Press, 1991:109-28.
18. 18 Decker K, Keppler D. Galactosamine hepatitis: key role of the nucleotide deficiency period in the pathogenesis of cell injury and cell death. Rev Physiol Biochem Pharmacol 1974; 71:77-105.
19. 19 Galanos C, Freudenberg MA, Rertter W. Galactosamine-induced sensitization to the lethal effects of endotoxin. Proc Natl Acad Sci USA 1979;76:5939-43.
20. 20 Chojkier M, Fierer J. D-Galactosamine hepatotoxicity is associated with endotoxin sensitivity and mediated by lymphoreticular cells in mice. Gastroenterology 1985;88:115-21.
21. 21 Kaplan JM, Smith AE. Transient immunosuppression with deoxyspergualin improves longevity of transgene expression and ability to readminister adenoviral vector to the mouse lung. Hum Gene Ther 1997;8:1095-104.
22. 22 Kuriyama S, Tominaga K, Mitoro A, et al. Immunomodulation with FK506 around the time of intravenous readministration of an adenoviral vector facilitates gene transfer into primed rat liver. Int J Cancer 2000;85:839-44.
23. 23 Yang Y, Greenough K, Wilson JM. Transient immune blockade prevents formation of neutralizing antibody to recombinant adenovirus and allows repeated gene transfer to mouse liver. Gene Ther 1996;3:412-20.
24. 24 Kuriyama S, Tominaga K, Kikukawa M, et al. Inhibitory effects of human sera on adenovirus-mediated gene transfer into rat liver. Anticancer Res 1998;18:2345-52.
25. 25 Kuriyama S, Tominaga K, Kikukawa M, et al. Transient cyclophosphamide treatment before intraportal readministration of an adenoviral vector can induce re-expression of the original gene construct in rat liver. Gene Ther 1999;6:749-57.
26. 26 Kuriyama S, Yoshikawa M, Tominaga K, et al. Gene therapy for the treatment of hepatoma by retroviral-mediated gene transfer of the herpes simplex virus thymidine kinase. Int Hepatol Commun 1993;1:253-9.
27. 27 Kuriyama S, Nakatani T, Masui K, et al. Bystander effect caused by suicide gene expression indicates the feasibility of gene therapy for hepatocellular carcinoma. Hepatology 1995;22:1838-46.
28. 28 Kuriyama S, Nakatani T, Masui K, et al. Evaluation of pro-drugs ability to induce effective ablation of cells transduced with viral thymidine kinase gene. Anticancer Res 1996;16: 2623-8.
29. 29 Kuriyama S, Sakamoto T, Masui K, et al. Tissue-specific expression of HSV-tk gene can induce efficient antitumor effect and protective immunity to wild-type hepatocellular carcinoma. Int J Cancer 1997;71:470-5.
30. 30 Kuriyama S, Masui K, Kikukawa M, et al. Complete cure of established murine hepatocellular carcinoma is achievable by repeated injections of retroviruses carrying the herpes simplex virus thymidine kinase gene. Gene Ther 1999;6: 525-33.
31. 31 Kuriyama S, Kikukawa M, Masui K, et al. Cytosine deaminase/5-fluorocytosine gene therapy can induce efficient anti-tumor effects and protective immunity in immunocompetent mice but not in athymic nude mice. Int J Cancer 1999;81:592-7.
32. 32 Kuriyama S, Kikukawa M, Masui K, et al. Cancer gene therapy with HSV-tk/GCV system depends on T-cell-mediated immune responses and causes apoptotic death of tumor cells in vivo. Int J Cancer 1999;83:374-80.
33. 33 Kuriyama S, Mitoro A, Yamazaki M, et al. Comparison of gene therapy with the herpes simplex virus thymidine kinase gene and the bacterial cytosine deaminase gene for the treatment of hepatocellular carcinoma. Scand J Gastroenterol 1999;34:1033-41.
34. 34 Cao G, Kuriyama S, Du P, et al. Construction of retroviral vectors to induce strong hepatoma cell-specific expression of cytokine genes. J Gastroenterol Hepatol 1996;11:1053-61.
35. 35 Cao G, Kuriyama S, Du P, et al. Complete regression of established murine hepatocellular carcinoma by in vivo tumor necrosis factor α gene transfer. Gastroenterology 1997;112:501-10.
36. 36 Cao G, Kuriyama S, Tsujinoue H, et al. A novel approach for inducing enhanced and selective transgene expression in hepatocellular carcinoma cells. Int J Cancer 2000;87: 247-52.
37. 37 Kanai F, Lan KH, Shiratori Y, et al. In vivo gene therapy for α-fetoprotein-producing hepatocellular carcinoma by adenovirus-mediated transfer of cytosine deaminase gene. Cancer Res 1997;57:461-5.
38. 38 Kanai F, Shiratori Y, Yoshida Y, et al. Gene therapy for α-fetoprotein-producing human hepatoma cells by adenovirus-mediated transfer of the herpes simplex virus thymidine kinase gene. Hepatology 1996;23:1359-68.
39. 39 Kaneko S, Hallenbeck P, Kotani T, et al. Adenovirus-mediated gene therapy of hepatocellular carcinoma using cancer-specific gene expression. Cancer Res 1995;55:5283-7.
40. 40 Brotodihardjo AE, Tait N, Weltman MD, et al. Hepatocellular carcinoma in western Sydney: aetiology, changes in incidence, and opportunities for better outcomes. Med J Aust 1994;161:433-5.
41. 41 Chawla Y, Santa N, Dhiman RK, et al. Portal hemodynamics by duplex Doppler sonography in different grades of cirrhosis. Dig Dis Sci 1998;43:354-7.
42. 42 Furuse J, Matsutani S, Yoshikawa M, et al. Diagnosis of portal vein tumor thrombus by pulsed Doppler ultrasonography. J Clin Ultrasound 1994;171:1097-104.
43. 43 Castell JV, Hernández D, Gómez-Foix AM, et al. Adenovirus-mediated gene transfer into human hepatocytes: analysis of the biochemical functionality of transduced cells. Gene Ther 1997;4:455-64.
44. 44 Nakamura T, Akiyoshi H, Saito I, et al. Adenovirus-mediated gene expression in the septal cells of cirrhotic rat livers. J Hepatol 1999;30:101-6.
45. 45 Bergelson JM, Krithivas A, Celi L, et al. The murine CAR homolog is a receptor for coxsackie B viruses and adenoviruses. J Virol 1998;72:415-19.
46. 46 Huard J, Lochmuller H, Acsadi G, et al. Differential short-term transduction efficiency of adult versus newborn mouse tissues by adenoviral recombinants. Exp Mol Pathol 1995;62:131-43.
47. 47 Dai Y, Schwarz EM, Gu D, et al. Cellular and humoral immune responses to adenoviral vectors containing factor IX gene: tolerization of factor IX and vector antigens allows for long-term expression. Proc Natl Acad Sci USA 1995;92: 1401-5.
48. 48 Muruve DA, Barnes MJ, Stillman IF, et al. Adenoviral gene therapy leads to rapid induction of multiple chemokines and acute neutrophil-dependent hepatic injury in vivo. Hum Gene Ther 1999;10:965-76. Gut 2000;47:571-574